Labcorp posts Q3 2026 growth, raises full‑year guidance and announces FDA melanoma test approval
Labcorp reported third‑quarter 2026 revenue of $3.81 billion, up 6.9% year‑over‑year, and adjusted earnings per share of $4.78, a 14.5% increase. The company lifted its full‑year 2026 revenue growth outlook to 5.9%‑6.7% and its adjusted EPS target to $18.30‑$18.70. It also received FDA approval for the PGDx elio® tissue complete CDx companion diagnostic for advanced melanoma and disclosed four acquisition agreements to expand its specialty‑testing portfolio.
Why it matters
The raised guidance signals higher expected earnings and cash flow for 2026, which could support a higher valuation for the stock (the company said the new EPS range reflects the quarter’s performance). The FDA approval adds a new revenue stream in oncology diagnostics, and the acquisitions are expected to be accretive to adjusted EPS in year one (Labcorp said each transaction is expected to be accretive).
Key facts
- 1Q3 2026 revenue was $3.81 billion, up 6.9% from $3.56 billion a year earlier. prnewswire.com
- 2Adjusted EPS for the quarter was $4.78, up 14.5% from $4.18 a year earlier. prnewswire.com
- 3Full‑year 2026 revenue growth guidance was raised to a range of 5.9%‑6.7% (mid‑point up 50 basis points). prnewswire.com
- 4Full‑year 2026 adjusted EPS guidance was raised to $18.30‑$18.70 per share (mid‑point up 18 cents). prnewswire.com
- 5The FDA approved the PGDx elio® tissue complete CDx as a companion diagnostic for advanced melanoma. stocktitan.net
- 6Labcorp announced acquisition agreements for assets of BioReference Health, Myriad Genetics’ prenatal health business, and Millennium Health, plus the earlier purchase of MLM Medical Labs. prnewswire.com
Summary written by AlphAI AI Desk from 20 of 20 sources. Not investment advice. Figures are as stated by the linked sources.